Protalix Biotherapeutics Appoints Moshe Manor To CEO And President

September 29, 2014 | Protalix Biotherapeutics, a biopharmaceutical company that develops and manufactures recombinant therapeutic proteins, announced that Moshe Manor will be the new President and Chief Executive Officer. The company, which is publicly traded on the New York Stock Exchange, announced that Manor will assume his office, taking over from retiring CEO and President David Aviezer, on November 2nd of this year. According to the Chairman of the company’s Board of Directors, “I am delighted that Moshe will be joining us as Chief Executive Officer. He brings extensive knowledge and vast senior experience, both in the generic and the innovative pharmaceutical world, from his years as Executive Vice President at Teva Pharmaceutical Industries.”